

UNITED STATE DEPARTMENT OF COMMERCE Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		TA AT	TORNEY DOCKET NO.
09/474,47	8 12/29/	99 LONGLEY		B	58434-A/JPW,
•	HM22/0713			E)	KAMINER
JOHN P WHITE			·	GITOMER.R	
COOPER & DUNHAM LLP 1185 AVENUE OF THE AMERICAS			l	ART UNIT	PAPER NUMBER
NEW YORK	NY 10036	AMERICAS .		1623 Date Mailed:	5
					07/13/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

2 . . 4

Application No. 09/474,478

Applicant(s)

Longley

Examiner

Ralph Gitomer

Group Art Unit 1623



☑ Responsive to communication(s) filed on <u>Dec 29</u> , 1999				
☐ This action is FINAL.				
☐ Since this application is in condition for allowance except in accordance with the practice under <i>Ex parte Quayle</i> , 1				
A shortened statutory period for response to this action is so is longer, from the mailing date of this communication. Faile application to become abandoned. (35 U.S.C. § 133). Exte 37 CFR 1.136(a).				
Disposition of Claims				
	is/are pending in the application.			
Of the above, claim(s)	is/are withdrawn from consideration.			
Claim(s)	is/are allowed.			
☐ Claim(s)				
☐ Claim(s)				
☐ Claims 1-38 are subject to restriction or election requ				
Application Papers				
\square See the attached Notice of Draftsperson's Patent Draft	wing Review, PTO-948.			
☐ The drawing(s) filed on is/are ob	ejected to by the Examiner.			
☐ The proposed drawing correction, filed on	is 🗖 approved 🗖 disapproved.			
$\hfill\Box$ The specification is objected to by the Examiner.				
$\hfill\Box$ The oath or declaration is objected to by the Examine	r.			
Priority under 35 U.S.C. § 119				
Acknowledgement is made of a claim for foreign prior	rity under 35 U.S.C. § 119(a)-(d).			
☐ All ☐ Some* ☐ None of the CERTIFIED copie	es of the priority documents have been			
received.				
$\hfill \square$ received in Application No. (Series Code/Serial	Number)			
$\hfill\Box$ received in this national stage application from	the International Bureau (PCT Rule 17.2(a)).			
*Certified copies not received:	·			
☐ Acknowledgement is made of a claim for domestic pr	iority under 35 U.S.C. § 119(e).			
Attachment(s)				
Notice of References Cited, PTO-892				
☐ Information Disclosure Statement(s), PTO-1449, Pape	r No(s).			
☐ Interview Summary, PTO-413				
☐ Notice of Draftsperson's Patent Drawing Review, PTC)-948			
☐ Notice of Informal Patent Application, PTO-152	•			
SEE OFFICE ACTION O	ON THE FOLLOWING PAGES			

The IDS received 4/24/00 has been entered and claims 1-38 are currently pending in this application.

This application contains claims directed to the following patentably distinct species of the claimed invention:

Methods of treating the following disorders:

Dermatitis

hyperpigmentation

asthma

5

10 cutaneous inflammations

anaphylaxis

bronchospasm

mastocytosis

urticaria

15 hypersensitivity reactions

tumors

contraception.

And independently the substances or mechanisms to treat the disorders:

20 inhibiting KIT protein

inhibiting chymase

inhibiting elastase

inhibiting SCF cleaving enzymes

inhibiting ligand binding with antibodies

-3-

With peptides
With non-peptides

inhibiting KIT dimerization
inhibiting downstream KIT activation
administering monoclonal antibodies of many different types
administering organic compounds.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, no claims are generic.

Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

5

10

15

20

-4-

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

The following prior art pertinent to applicant's disclosure is made of record and not relied upon:

Brownell (5,911,988) teaches treating asthma using SCF antibody.
Bennett (5,997,865) teaches FLK antibodies.

Ravetch (5,877,396) teaches Fc receptors and antiinflammatory agents.

20

25

15

5

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ralph Gitomer whose telephone number is (703) 308-0732. The examiner can normally be reached on Tuesday-Friday from 8:00 am - 5:00 pm. The examiner can also be reached on alternate Mondays. If

-5-

attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Geist can be reached on (703) 308-1701. The fax phone number for this Art Unit is (703) 308-4556. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-1234.

Ralph Gitomer Primary Examiner Group 1623

Recloures

RALPH GITOMER PRIMARY EXAMINER GROUP 1200

10

5